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Abstract: Live imaging of neuromuscular junctions (NMJs) in situ has been constrained by the
suitability of ligands for inert vital staining of motor nerve terminals. Here, we constructed sev-
eral truncated derivatives of the tetanus toxin C-fragment (TetC) fused with Emerald Fluorescent
Protein (emGFP). Four constructs, namely full length emGFP-TetC (emGFP-865:TetC) or trunca-
tions comprising amino acids 1066–1315 (emGFP-1066:TetC), 1093–1315 (emGFP-1093:TetC) and
1109–1315 (emGFP-1109:TetC), produced selective, high-contrast staining of motor nerve terminals
in rodent or human muscle explants. Isometric tension and intracellular recordings of endplate
potentials from mouse muscles indicated that neither full-length nor truncated emGFP-TetC con-
structs significantly impaired NMJ function or transmission. Motor nerve terminals stained with
emGFP-TetC constructs were readily visualised in situ or in isolated preparations using fibre-optic
confocal endomicroscopy (CEM). emGFP-TetC derivatives and CEM also visualised regenerated
NMJs. Dual-waveband CEM imaging of preparations co-stained with fluorescent emGFP-TetC
constructs and Alexa647-α-bungarotoxin resolved innervated from denervated NMJs in axotomized
WldS mouse muscle and degenerating NMJs in transgenic SOD1G93A mouse muscle. Our findings
highlight the region of the TetC fragment required for selective binding and visualisation of motor
nerve terminals and show that fluorescent derivatives of TetC are suitable for in situ morphological
and physiological characterisation of healthy, injured and diseased NMJs.
Keywords: neuromuscular junction; tetanus toxin; imaging
1. Introduction
Differential diagnosis of neuromuscular abnormalities or motor neuron diseases such
as amyotrophic lateral sclerosis (ALS) is commonly based on combinations of biomarker
readings, neurophysiological investigation, pathology in muscle biopsies and clinical
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experience with reference to agreed international protocols [1–5]. Non-invasive or mini-
mally invasive imaging methods using, for example, computerised tomography (CT) or
magnetic resonance imaging (MRI) can also provide insight into gross neuromuscular
pathology [6–9]. However, early signs of motor neuron pathology or axonal injury include
disruption of motor nerve terminals and endplates at neuromuscular junctions (NMJs)
and to visualise this pathology in situ requires micrometre image resolution, which cannot
currently be achieved using techniques such as CT or MRI [10–16].
Confocal endomicroscopy (CEM) utilises laser scanning and fluorescence capture via
hundreds of optical filaments contained in narrow (0.5–1.5 mm) probes. This technology
has enabled real time (up to 12 video frames per second), direct imaging of cells either
selectively expressing fluorescent proteins or stained with exogenous ligands conjugated
to specific fluorochromes [17–19]. We showed previously that CEM visualises motor
nerve terminals in mice expressing Yellow Fluorescent Protein (YFP) selectively in motor
neurons [20]. Innervated or denervated NMJs could also be distinguished by combining
CEM with conventional electromyography in these mice [21]. However, wider application
of CEM for research, or veterinary or clinical diagnostic applications, would require non-
toxic, high-contrast fluorescent ligands for axons and NMJs that can be administered
exogenously, for example by local subcutaneous or intramuscular injection. We confirmed
previously that 4-di-2-Asp, a fluorescent styryl dye that passively stains motor nerve
terminals [22,23], and a green fluorescent protein (GFP)-tagged construct of a botulinum
toxin heavy chain that also binds to NMJs [24,25] both readily enabled visualisation of
motor nerve terminals using conventional wide-field or laser scanning confocal microscopy
(LSCM). However, the intensity and contrast of the fluorescence of these molecules were
insufficient for routine visualisation of NMJs using fibre-optic CEM, whose sensitivity is
less than that of conventional LCSM systems or wide-field fluorescence microscopes [21].
Motor nerve terminals contain ganglioside and peptide binding sites that selectively
adhere fluorescent conjugates of the tetanus toxin heavy chain (comprising non-toxic B
and C fragments), from which the toxic light chain (A fragment) has been removed [26–29].
Remarkably, truncations of TetC from the N-terminus were shown previously to improve
binding to ganglioside receptors [30]. In the present study we therefore investigated the
potential for staining and CEM visualisation of motor nerve terminals using full length
and truncated derivatives of the C-fragment (TetC), fused at the N-terminus to Emerald
Fluorescent Protein (emGFP), a brighter variant of Green Fluorescent Protein [31], that
retained the nerve terminal receptor binding domain [32–34]. We tested the suitability of
these potential ligands for vital staining of motor nerve terminals and their visualisation
with single or dual-waveband CEM.
We found that fusion proteins containing 206 or more amino acids from the C-terminus
of TetC produced high-contrast, selective staining of motor nerve terminals. Electrophysio-
logical analysis showed that emGFP-TetC constructs were physiologically inert since they
did not acutely alter neuromuscular synaptic transmission or function. Nerve terminal
staining was readily visualised using CEM optical fibre probes when these were applied to
skeletal muscles of either healthy mice, or to slowly-degenerating axotomized terminals in
WldS mutant mice or in the SOD1G93A mouse model of motor neuron disease. Our findings
show that one-step vital staining of nerve terminals with truncated TetC fragments and
labelled α-bungarotoxin (BTX), combined with dual-waveband CEM imaging, comprise a
potentially powerful combination that could facilitate analysis of neuromuscular synaptic
form and function at normal, damaged or diseased NMJs.
2. Materials and Methods
2.1. Ethics, Animals and Tissues
Isolated nerve-muscle preparations were made from adult (1–8 month old) stock mice
of C57Bl6, CD01, WldS, thy1.2YFP16-WldS, or SOD1G93A strains bred and maintained in
University of Edinburgh, University of Sheffield or University of Glasgow animal care
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facilities under conditions approved by local ethical committees, closely monitored by ap-
pointed Veterinary Officers, and regularly inspected under licence by the UK Home Office.
With local ethical committee approval and under Home Office Licences, some mice
were anaesthetised with isoflurane and volumes of saline (up to 100 µL) containing
physiologically-inert, Emerald Fluorescent Protein (emGFP)-tagged tetanus toxin C frag-
ments (emGFP-TetC; see below) were injected subcutaneously in one hind limb. The an-
imals were sacrificed 20–30 min later. In other experiments, mice were injected with
5 mg/kg carprofen and/or 0.05–0.3 mg/kg buprenorphine, anaesthetised with isoflurane
and the sciatic nerve in the thigh was then exposed on one side through a small skin
incision. For study of slow nerve-terminal degeneration in WldS mice, the nerve was cut
with micro-scissors; and for study of axonal and nerve terminal regeneration, in wild-type
mice, the nerve was crushed between the tips of fine forceps. The wounds were closed
with 6/0 silk suture or wound clips before returning mice to home cages for 5–21 days.
Mice were inspected daily for signs of discomfort by veterinary surgeons or other qualified
animal care staff.
For terminal investigations, animals were sacrificed by anaesthetic overdose and
cervical dislocation, in compliance with UK Home Office Schedule 1. Extensor digitorum
longus (EDL), soleus (SOL), flexor digitorum brevis (FDB) or deep lumbrical (DL) muscles in
the hind limbs, epitrochleoanconeus (ETA) in the forelimb, or triangularis sterni (TS) muscles
in the thorax were rapidly dissected and immersed in mammalian physiological saline
(MPS) of composition (mM): NaCl (158), KCl (5), CaCl2 (2), MgCl2 (1), glucose (5), HEPES
(5), adjusted to pH 7.2–7.4 with HCl or NaOH. Solutions were bubbled with air for at least
20 min.
2.2. Human Tissue: Ethics and Sampling
Anonymised human tissue was obtained in accordance with the guidelines of the Dec-
laration of Helsinki and approved by the Institutional Review Board of the NHS Lothian
Ethics Committee (REC 2002/1/22; 2002/R/OST/02) and NRS BioResource (15/ES/0094,
SR719, SR769; 15/SS/0182, SR589) and with informed consent. Muscle samples were
obtained as described previously [35] from surgical patients undergoing lower limb ampu-
tation for complications of peripheral vascular disease, typically either critical ischemia in a
non-salvageable limb, or failure of previous vascular reconstruction. Samples of the soleus
muscle were dissected in the operating theatre from the discarded distal limb immediately
after its surgical amputation. Tissue was harvested from the proximal end, close to the line
of surgical incision and away from areas of necrosis or infection. Small blocks of tissue,
containing full-length muscle fibres from origin to insertion (approx. 2 cm in length) were
removed from each of the muscles selected and immersed in vials containing 10–20 mL
of standard 0.2 M phosphate-buffered saline (PBS). The specimens were then dispatched
to the laboratory, where small bundles of muscle fibres in the region of innervation were
dissected in MPS.
2.3. GFP-TetC Constructs
A full-length synthetic tetanus toxin C-fragment gene was synthesised in similar
fashion to that described previously [36]. For tagging with Green Fluorescent Protein (GFP),
a fully synthetic genetic sequence was prepared comprising the GFP gene from Aequorea
Victoria and the Hc region sequence from the Clostridium tetani neurotoxin (TeNT-Hc) was
synthesised using a codon bias optimised for expression in Escherichia coli. Restriction sites
BamHI and XbaI were incorporated at the 5′ and 3′ ends, respectively, to allow subcloning
into expression vectors. GFP-TeNT-Hc-encoding fragments were subcloned into the vector
pMAL-c2x (New England Biolabs, Ipswich, MA, USA) and expressed as maltose binding
protein (MBP) fusions in the host strain BL21 (Novagen, Darmstadt, Germany). A single
colony was inoculated into 200 mL of Terrific Broth (24 g/L yeast extract, 12 g/L tryptone,
9.4 g/L KH2PO4, 2.2 g/L K2HPO4, pH 7.2) supplemented with 100 µg/mL ampicillin and
0.5% (w/v) glucose and grown overnight at 30 ◦C in a shaking incubator. Cultures were
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diluted 1:6 with fresh medium and grown to an OD600 of approximately 2.0 at 30 ◦C. IPTG
was added (500 µM) and cultures grown for 2 h at 25 ◦C. Cell pellets were resuspended
in 20 mM Tris-HCl pH 7.4, 500 mM NaCl, 1 mM EDTA (binding buffer) and lysed by
sonication. Cell debris was removed by centrifugation at 27,000× g and the supernatant
fluid applied to a 5 mL amylose resin (NEB) column equilibrated in the binding buffer.
After washing with binding buffer, the fusion protein was eluted with binding buffer
supplemented with 10 mM maltose. MBP was removed from fusion proteins by treatment
with factor Xa protease (1 U/mg) at 20 ◦C for 18 h in the elution buffer. GFP-TetC proteins
were purified by anion exchange (Mono-Q) chromatography and then dialysed against
20 mM HEPES pH 7.4 containing 200 mM NaCl.
2.4. Truncated TetC Constructs
Overlapping, complementary forward and reverse primers were generated using
the sequence for tetanus toxin heavy chain found on Uniprot (entry: PO4958) or NCBI
(AM412776). The tetanus C-fragment sequence was inserted into a pET28 vector down-
stream of eGFP and a HIS6-tag. For the replacement of eGPF by emGFP, the emGFP
sequence was ordered as a gBlock from Integrated DNA Technologies (Leuven, Belgium)
with an NdeI site at the 5′ end and a BamHI site at the 3′ end. The sequence was amplified
by hi-fidelity PCR and the purified PCR product was digested with NdeI and BamHI in
NEB4 buffer before purification using the Zyppy Clean (Zymo Research, Cambridge, UK)
and concentrator kit according to manufacturer’s instructions. The insert was ligated into
the NdeI and BamHI cut pET28-eGFP-TetC vector. Ligation was done in a 1:3 ratio and
incubated overnight at room temperature. Constructs were transformed into Invitrogen
Top10 competent E. coli cells and plasmid extracted using the Qiagen plasmid mini prep kit
according to manufacturer’s instructions. All constructs were confirmed by Sanger sequenc-
ing. Truncations were designed for regions of interest, according to the crystal structure
of the heavy-chain from EMBL-EBI [37] and effected by restriction free In-Fusion cloning
generating the indicated deletions of the N-terminal region of TetC. Primer sequences will
be provided upon request to the appropriate corresponding author (P.A.S.).
2.5. DNA Extraction from Bacteria
Top10 competent E. coli were grown in 5 mL or 100 mL and the Qiagen Mini or Midi
prep kit, respectively, were used according to manufacturer’s instruction. Purified DNA
was then used in either further cloning experiments or protein expression.
2.6. Bacterial Expression and Protein Purification
Rosetta-DE3-pLys cells were electroporated with 10 ng of expression plasmid DNA
and plated on Kanamycin + Chloramphenicol plates and grown overnight at 37 ◦C. Single
colonies were used to inoculate LB broth and grown to an OD600 of ~0.7 before adding
isopropyl b-D-thiogalactopyranoside (IPTG) to 1.5 mM and 2% ethanol and incubated at
room temperature overnight. Cultures were harvested by centrifugation (6000 rpm, 4 ◦C,
15 min) and the bacterial pellet washed once in PBS. The pellet was then resuspended in
lysis buffer (10 mM HEPES, pH 7.9, 500 mM NaCl, EDTA-free protease inhibitor Complete
(Roche) and the cells sonicated (six times, 30 s) before a final centrifugation (13,000 rpm,
30 min) to remove bacterial debris. The supernatant was purified on a Ni2+NTA column
(Qiagen, Venlo, The Netherlands) and eluted using an Imidazole gradient from 50 mM
to 350 mM. Eluted fractions were pooled and dialyzed against PBS using a Vivaspin4
spin column. Protein was stored at −80 ◦C for long term storage or at 4 ◦C for short
term storage.
2.7. Fluorescence Measurements of TetC Conjugates
Fluorescence of emGFP and eGFP constructs were compared fluorometrically. Stan-
dard curves ranging from 0.05–1 mg protein/mL were prepared and the fluorescence at
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each concentration measured in a TD-700 fluorometer (Turner Designs, San Jose, CA, USA).
Protein concentration was measured using the nanodrop and absorbance at 280 nm.
2.8. Alexa488 Labeling of TetC Constructs
Some TetC constructs were labelled with Alexa Fluor 488 instead of fusion to emGFP.
Alexa Fluor™ 488 Protein Labeling Kits from Invitrogen were used to label TetC proteins
according to the manufacturer’s protocol. However, since the truncated TetC proteins were
smaller than 30 kDa they were purified using Ni-NTA agarose rather than the columns
provided. After column washing with 10 mM imidazole in elution buffer, protein was
eluted in elution buffer provided in the kit and the addition of 350 mM imidazole. All eluted
proteins were concentrated and the buffer exchanged against PBS. Protein concentration
was determined by absorbance at 280 nm. Labelled constructs were stored at 4 ◦C.
2.9. TetC Staining and LSCM Imaging
Muscles were dissected in MPS. Dissected preparations were pinned by their tendons
in petri dishes lined with Sylgard (Dow, Dewsbury, UK) then incubated with 5–200 µg/mL
GFP-865:TetC or other emGFP-TetC constructs for 20–60 min at room temperature, followed
by at least one 15 min wash. We confirmed that emGFP alone did not stain NMJs (data not
shown). Some muscles were counterstained by incubation for 10–20 min in either TRITC-α
-BTX or Alexa647-α-BTX (Invitrogen-Life Technologies, Paisley, UK; 2–5 µg/mL in MPS).
The muscles were then washed twice with MPS for 10 min and imaged using either an
Olympus BXII epifluorescence microscope via Hamamatsu C5810 or Orca ER cameras
interfaced to Openlab (Improvision, Coventry, UK) software running on an Apple Mac
PowerPC, or using a BioRad Radiance 2000 laser scanning confocal microscope (LSCM;
Biorad, Hemel Hempstead, UK) via a 40× water dipping objective lens mounted on a
Nikon Eclipse E600FN epifluorescence microscope. Specimens were scanned with Argon
(488 nm), HeNe (543 nm) or red diode lasers (637 nm), normally at 500 lps, and images
z-series were captured at either 512 × 512 or 1024 × 1024 pixels resolution. Some images
were obtained using a Zeiss LSM 880 confocal microscope and z-series rendered in 3D
using Imaris 9.6.1 (Bitplane, Zurich, Switzerland).
For quantification of nerve terminal fluorescence with increasing concentration of
GFP-865:TetC, images were captured in the epifluorescence microscope at fixed exposure
and camera gain and pixel intensity, averaged in regions of interest enclosing a motor nerve
terminal, at 20 min intervals using Openlab software, while progressively increasing the
concentration of GFP-865:TetC (15 min washes before imaging at each concentration).
Fluorescence recovery after photobleaching (FRAP) was carried out in the Radiance
2000 confocal microscope using an inbuilt procedure in Lasersharp software. A reference
image was first obtained, then the argon laser was scanned at maximum laser power on a
small (approximately 50 × 50 pixels) region of interest (ROI) covering part of the terminal.
Subsequent 512 × 512 pixel images of the whole terminal were obtained at 500 lps with
constant, reduced laser power (1% of maximum), at 10 min intervals over the following
hour. Fluorescence intensity of the bleached region was expressed as a percentage of the
maximum intensity at the same laser power setting, before bleaching.
2.10. Tension Measurements and Electrophysiology
For isometric tension recording, isolated mouse FDB muscles were pinned by their
distal tendons to the base of a Sylgard-lined chamber and bathed in MPS (10 mL). The
proximal tendon was attached to an ML102 force transducer (AD Instruments, Oxford, UK)
and the tibial nerve was aspirated into a capillary glass-tipped suction electrode connected
to a DS2 Stimulator (Digitimer, Welwyn Garden City, UK), then stimulated with pulses
0.1–0.2 ms in duration and nominally up to 10 V amplitude at frequencies of 0.5–50 Hz.
Stimulus trains (2–50 Hz, for up to 2 s) were triggered via a Powerlab 26T interface (AD
Instruments), which was also used to measure force production, using Labchart 7 software
(AD Instruments, Oxford, UK) running on an Apple iMac computer. Muscles were either
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preincubated in emGFP-TetC constructs (20–100 µg/mL) for 30 min then transferred to
the chamber and recordings made in MPS, or the constructs were added to MPS in the
recording chamber and recordings made 30–60 min later, with or without subsequently
washing the preparations. Analysis was carried out offline using Labchart 7/8.
Intracellular recordings were made from mouse FDB or ETA preparations pinned by
their distal and proximal tendons to a Sylgard-lined recording chamber and the muscle
nerves stimulated using suction electrodes. Muscle action potentials and contractions were
blocked by preincubating the muscles in µ-conotoxin GIIIB (µCTX-GIIIB; Sigma-Aldrich,
Glasgow, UK) at a concentration of 1–2 µg/mL in MPS for 20–30 min. Microelectrodes
were pulled with a Sutter P87 puller, filled with 3 M KCl (resistance typically 20–50 MΩ)
and mounted on an MP-85 manipulator (WPI-Europe, Hitchin, UK). FDB muscle fibres are
less than 1 mm in length and therefore isopotential, so it was not necessary to position the
electrode tip precisely in the endplate region in order to record endplate potentials with
high fidelity [13,38]. For ETA recordings, NMJs were initially located using differential
interference contrast microscopy and subsequently by fluorescence microscopy after la-
belling them with full length emGFP-865:TetC. Labelled NMJs were imaged using a Zeiss
LSM 880 confocal microscope. In either FDB or ETA muscles, membrane potential and end-
plate potential (EPP) recordings were obtained using an Axoclamp 2B or 900A amplifiers
connected to a CED Micro1401 interface (Cambridge Electronic Design, Cambridge, UK) or
Digidata 1550B [Molecular Devices, San Jose, CA, USA) and digitised at 50 kHz using a
PC running WinWCP (Strathclyde Electrophysiological Software, Glasgow, UK), Spike2
(Cambridge Electronic Design) or ClampEx (Molecular Devices) software. Stimulation, via
a Digitimer DS2 stimulator (up to 10 V, 0.2 ms), was triggered either using the Micro1401
or Digidata interfaces, or a Digitimer 4030 Programmer. Nerve-evoked endplate potentials
(EPPs) or spontaneous miniature EPPs (MEPPs) were recorded either from preparations
pre-incubated in emGFP-TetC constructs or after adding the emGFP-TetC constructs to the
recording chamber (20–100 µg/mL in MPS). Analysis of EPPs and MEPPs was carried out
offline using either WinWCP, Minianalysis (Synaptosoft, Atlanta, GA, USA), or pClamp 10
(Molecular Devices, Sunnyvale, CA, USA) software. Amplitudes were corrected to a stan-
dard membrane potential of −70 mV, assuming a transmitter reversal potential of −5 mV
(Vc = Vo.65/(Em-5); where Vc is the corrected voltage, Vo the observed amplitude and Em
the positive (inverted) value of the observed resting membrane potential), before graphical
summary and statistical comparison.
2.11. Confocal Endomicroscopic (CEM) Imaging
CEM imaging was carried out using either single-waveband (488 nm diode laser
excitation) or dual-waveband (488 nm and 660 nm diode laser excitation) Cellvizio® instru-
ments (Mauna Kea Technologies, Paris, France) fitted with 1.5 mm diameter, Proflex S-1500
optical fibre probes. Pilot experiments were performed initially at the Kroto Research Insti-
tute, Sheffield using a dual waveband CEM instrument (DW-CEM) in this facility, with the
assistance of Dr Nicola Green, and continued in Edinburgh with a different DW-CEM sys-
tem rented from Mauna Kea Technologies. Probes were calibrated in accordance with the
manufacturer’s instructions. For DW-CEM, preparations were simultaneously incubated
for 20–30 min in Alexa647-α-bungarotoxin (5–10 µg/mL) and either full length emGFP-
865:TetC or truncated constructs (20–50 µg/mL) then washed for 20 min in MPS. The tip of
the CEM probe was applied to muscle surfaces, as described previously [20,39]. Image se-
quences (videos) were captured in real time at 12 frames per second (fps) and individual im-
age frames were extracted and saved in .jpg, .png or .tiff formats. Image sequences were pro-
cessed in FiJI, downloaded from https://imagej.net/software/fiji/ (accessed on 10 Septem-
ber 2021). In some instances, images of NMJs were stabilised and aligned using the Stack-
Reg/TurboReg plugins, downloaded from http://bigwww.epfl.ch/thevenaz/stackreg/
(accessed on 10 September 2021).
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2.12. Statistics and Graphics
Quantitative data were statistically analysed and graphed using software tools in
Microsoft Excel and Prism 7 (Graphpad, San Diego, CA, USA).
3. Results
We describe first conventional microscopy of NMJs labelled with fluorescent deriva-
tives of the tetanus toxin C-fragment (TetC). Second, we show from functional and elec-
trophysiological recordings that labelled TetC constructs do not impair neuromuscular
transmission, suggesting they may be safe to use in vivo. Third, we describe visualisa-
tion of nerve terminals stained with fluorescent TetC constructs using single- or dual-
waveband CEM.
3.1. GFP-TetC Constructs Selectively Stain Motor Nerve Terminals
We initially tested a clone of the complete tetanus toxin C-fragment, also known as
the Hc component of the heavy chain, comprising 458 amino acids numbered from amino
acids 857–1315 in the full-length toxin. This construct therefore excluded both the toxic
light chain (A fragment) and the membrane translocation region (B or Hn fragment) of the
full-length tetanus toxin protein [30]. We tagged and co-expressed the C-fragment with
Green Fluorescent Protein at the N-terminus (GFP-TetC). Incubation of isolated mouse
muscles with GFP-TetC for 20–40 min, at concentrations ranging from 5–100 µg protein/mL
produced selective, concentration-dependent labelling of motor nerve terminal membranes,
with high contrast and low levels of background fluorescence (Figure 1). Conventional laser
scanning confocal microscopy (LSCM) of unfixed, vitally-stained preparations revealed
binding of GFP-TetC both diffusely and at punctate aggregates (‘hotspots’; Figure 1A,
inset) in the motor nerve terminal membrane, as indicated also in other studies [28]. This
pattern of staining was stable at room temperature for at least 4 h. In preparations from
adult mice, although short lengths of the preterminal axon were also stained, myelinated
regions of the axons were not labelled (Figure 1A–C, arrows). We attempted post-fixation
immunostaining of preparations with neurofilament and SV2 after imaging junctions vitally
stained with GFP-TetC. However, the GFP-TetC staining of nerve terminals did not endure
fixation very well, so our attempts to co-localise TetC and Sv2 were not successful.
We investigated the stability of bound GFP-865:TetC further by measuring fluorescence
recovery after photobleaching (FRAP) of regions of interest (ROIs) enclosing part of the
nerve terminal. After bleaching these circumscribed ROIs, partial recovery of fluorescence
occurred in the bleached region with a recovery time constant of 14.3–15.5 min, suggesting
that the binding sites for GFP-865:TetC were mobile, but unlikely to be freely diffusible
within the plane of nerve terminal plasma membranes (Figure 2). Recovery of fluorescence
also occurred in bleached regions containing hot-spots (recovery 50–80%, time constant
22–44 min, n = 3 NMJs/muscles), suggesting that tetanus-toxin binding sites were also
readily recruited into these sites. We did not investigate the mobility of TetC binding sites
further in the present study.




Figure 1. GFP-tagged TetC staining of motor nerve terminals is concentration dependent. (A–C):
LSCM images of an NMJ in an unfixed mouse TS muscle vitally stained with 100 µg/mL of full-
length GFP-TetC and 5 µg/mL TRITC-α-bungarotoxin. (A): GFP-TetC uniformly stained motor
nerve terminals but not their preterminal axons. Both diffuse and concentrated staining (‘hotspots’;
arrows and inset) was typically observed; (B): Counterstaining with TRITC-α-bungarotoxin staining
of postsynaptic AChR; (C): Merged image showing alignment of presynaptic staining with slight
extension of AChR staining beyond the margins of the nerve terminal staining. (D): Wide-field
fluorescence images of motor nerve terminals in mouse FDB muscles stained with progressively
increasing concentrations (12.5–100 µg/mL, as indicated) of GFP-TetC. (E): Graph of ratio of nerve
terminal fluorescence to background fluorescence (∆F/F0) versus GFP-TetC concentration. Fluo-
rescence ratio was calculated from the difference between average intensity in a region of interest
(ROI) including a continuous portion of the NMJ (range of areas 575 to 1650 pixels) selected using the
‘magic wand’ tool in Fiji, compared with that in a background region outside the NMJ. Discernible
staining of NMJs was observed with concentrations about 10 µg/mL but brighter, higher contrast
staining was observed at concentrations between 50–100 µg/mL.
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Figure 2. TetC binding sites are mobile within the nerve terminal membrane. (A): Sequence of LSCM
images of an unfixed mouse TS NMJ showing recovery of fluorescence after photobleaching (FRAP)
of the region indicated (yellow outlined box) in the first image of the sequence. Subsequent images
were captured at fixed laser power at the times indicated during the following 60 min. (B): Images of
the showing recovery of fluorescence in the expanded region indicated in A. Yellow arrow indicates
the bleached region in this NMJ. (C): Graphs of FRAP from two separate experiments (preparations
from different mice) based on measurements in diffusely stained regions of the motor nerve terminals.
(D): Graphs of FRAP from three different experiments (preparations from different mice) based on
measurements in punctate-stained, hotspot regions of motor nerve terminals. The relatively slow
rates of FRAP suggest a slower process of redistribution of labelled TetC receptor proteins than
expected by passive diffusion.
3.2. Truncated emGFP-TetC Constructs Also Stain Nerve Terminals
Next, we modified GFP-TetC, first by substituting GFP with a brighter fluorescent
protein variant, “Emerald” fluorescent protein (emGFP) [31]. The constructs we made and
examined for fluorescent staining of motor nerve terminals are illustrated in Figure 3A–C.
We refer to our constructs with reference to the N-terminal amino acid to the amino acid
location in full length tetanus toxin. Thus, from hereon we refer to the full length (FL)
C-fragment as 865:TetC, and the N-terminally truncated fragments we studied as 1066:TetC,
1093:TetC, 1109:TetC and so on. When we compared the fluorescence of these constructs
ligated with either eGFP or emGFP, it appeared that the fluorescence of constructs labelled
with emGFP were about twice as bright as those labelled with eGFP (Figure 3D).
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Figure 3. Truncated TetC constructs labelled with emGFP are brightly fluorescent. (A): Schematic
diagram showing the three principal domains of intact tetanus toxin, including the toxic light
chain (A) and inert heavy chain, comprising Translocation (B) and Receptor binding (C) domains.
(B): Schematic showing association of emerald Fluorescent Protein (emGFP) with TetC constructs
made in the present study, comprising variable numbers of amino acids from their truncated N-
terminuses (nnnn-TetC); areas drawn in proportion to the molecular weights of GFP and TetC. (C):
Full length TetC contains 458 amino acids, numbered 865–1315 at the C-terminus of complete tetanus
toxin (light + heavy chains). In the present study, we compared truncations at amino acid 1066–1298,
as indicated. Yellow bars indicated positive staining of motor nerve terminals (see Figure 4), blue
bars indicated no staining. (D): Fluorometric data (duplicated) comparing fluorescence of truncated
TetC constructs labelled either with enhanced GFP (eGFP-1066) or with emGFP (emGFP-FL = full
length; emGFP-1093; or emGFP-1109, referring to constructs emGFP-865:TetC; emGFP-1066:TetC,
emGFP-1093:TetC or emGFP-1109:TetC). emGFP labelled constructs were about twice as bright at
the same protein concentration as eGFP labelled constructs. Filled circles are resulrs of individual
fluorometric measurements, bars are the mean of these in each instance.
Next, we tested the effect of truncating TetC on selective labelling of motor nerve
terminals, expressing emGFP at the N-terminus of the truncated construct (Figure 4). The
appearance of motor nerve terminals labelled with emGFP was similar to those labelled
with GFP or to TetC fragments labelled by conjugation with Alexa 488 (Figure 4A,B). We
found that emGFP-1066:TetC, a protein fragment comprising amino acids 1066–1315 only
(that is, the 249 C-terminus amino acids of TetC) also produced strong and reliable staining
of mouse, rat and human NMJs (Figure 4C). Similar results were obtained with a shorter
construct, emGFP-1093:TetC, containing 222 C-terminal amino acids. We did not compare
quantitatively the fluorescence intensity of these bound TetC constructs but, consistent with
previous reports of improved receptor binding [30], our subjective impression was that flu-
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orescence was brighter with emGFP-1093:TetC and emGFP-1066:TetC compared with full
length emGFP-865:TetC. However, we did not test in the present study whether simultane-
ous staining of different preparations with emGFP-TetC variants produced quantitatively
different fluorescent staining intensities. Thus, our subjective impression is subject to
quantitative validation. A construct truncated at amino acid 1109 (emGFP-1109:TetC; 206
C-terminus amino acids) also produced strong initial staining of NMJs (Figure 4C) but this
was relatively transient; nerve terminal fluorescence intensity and contrast were typically
degraded over the following 2–4 h (see below). This was possibly due to increased uptake
and axonal transportation but we did not explore the mechanism further in the present
study. Constructs containing 178 or fewer C-terminus amino acids (Figure 3B, blue bars)
showed no overt NMJ staining at concentrations up to 200 µg/mL (data not shown).
α
α
Figure 4. emGFP-TetC derivatives stain rodent and human motor nerve terminals. (A): LSCM image
of unfixed motor nerve terminals in mouse TS muscle vitally stained with 50 µg/mL emGFP-865:TetC
(full length TetC); (B): merged LSCM mouse TS NMJs stained with an Alexa488-tagged full length
TetC construct (green fluorescence) and AChR counterstained with TRITC-α-bungarotoxin (red
fluorescence; colocalised staining yellow); (C): Merged LSCM images of NMJs counterstained with
TRITC-α-bungarotoxin and TetC constructs truncated at the N-terminal amino acids indicated, in
mouse, rat and human muscle explants. All the constructs indicated produced NMJ staining (staining
of human explants with emGFP-1109:TetC was not attempted). Insets in (B,C) show the fluorescent
green channel (displayed as grey) for each image.
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3.3. emGFP-TetC Constructs Stain Neonatal Motor Nerve Terminals
TetC fragments also stained motor nerve terminals in neonatal muscle preparations.
Figure 5A–D shows images of NMJs in isolated triangularis sterni (TS) muscles stained
with emGFP-1093:TetC in muscles dissected from neonatal rats aged 3–10 days postnatal
(P3-P10). In addition to staining NMJs, emGFP-1093:TetC also revealed the characteristic
overgrowth of motor axons normally associated with immature, polyneuronally innervated
NMJs [40,41]. By P10, however, axonal staining appeared fainter (Figure 4D) and, as
reported above, was largely absent in adult preparation (Figure 5E). It remains unclear
whether this decrease then loss of axonal staining is due to postnatal loss of receptor for
the TetC ligand in axonal membranes, or to exclusion of the dye from axonal binding sites
by the compacted myelin sheath, which is the last to form during NMJ development [42].
α
Figure 5. emGFP-TetC constructs also stain neonatal NMJs. (A–D): LSCM images of the motor
innervation of unfixed TS muscle preparations from rats of the postnatal ages (in days, P3–P10)
indicated, co-stained with emGFP-1093:TetC and TRITC-α-bungarotoxin. Motor nerve terminals
(yellow) and axons (green) that were polyneuronally innervating NMJs were visible at this age.
Arrows indicate staining of intramuscular and preterminal axons. (E): By contrast, emGFP-1093:TetC
intensely stained motor nerve terminals (inset) in an adult (about 150 g) rat TS preparation but, as in
adult mice, the preterminal axon (cyan arrow) appeared largely unstained.
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3.4. emGFP-TetC Constructs Also Stained Other Cell Types
In some preparations, emGFP-Tet constructs produced notable, additional labelling of
sparsely distributed axons. However, these axons were not α-motor axons terminating at
NMJs. Close inspection of LSCM z-series showed that many of these axons were associated
with blood vessels or passed through connective tissue overlying NMJs (Figure 6A–C;
Supplementary Videos S1 and S2). We presumed these to be either unmyelinated sensory
axons or autonomic motor axons [43–45]. There was also no evidence that emGFP-TetC
constructs stained either myelinating Schwann cells, terminal Schwann cells, or kranocytes
localised to NMJs [13,46]. However, in some preparations unidentified cells resembling
fibroblasts or macrophages, and that were not selectively localised to NMJs, were also
labelled (Figure 6C,D). We did not investigate these ectopic binding sites further in the
present study.
α
Figure 6. emGFP-TetC constructs also stain unmyelinated axons and unidentified non-neuronal
cells. (A): Low power LSCM image of an unfixed mouse ETA preparation vitally stained with
emGFP-865:TetC. In addition to nerve terminal staining, a network of axonal staining (arrows) was
also visible, not terminating at NMJs and likely to be unmyelinated axons of intramuscular sensory
axons or vascular autonomic motor axons (see also Supplementary Videos S1 and S2). (B): Higher
power image of the same preparation as A, showing probable unmyelinated autonomic/sensory
axonal staining. Note that although these axons in this maximum intensity projection LSCM image
may appear to end on NMJs, inspection of the image z-series indicated clearly that they were not
(images not shown); (C,D): In addition to axonal staining (arrows), in some preparations emGFP-TetC
constructs evidently stained unidentified non-neuronal cells (asterisks), possibly macrophages.
In sum, we found that protein fragments about half of the full length TetC C-terminal
fragment retain capacity for selective binding to nerve terminal membranes [30]. When
conjugated with GFP or related proteins, these constructs give rise to high-contrast, selective
staining of motor nerve terminals. emGFP-TetC constructs also produced additional
staining of unmyelinated axons and other, as yet unidentified, cell types.
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3.5. emGFP-TetC Constructs Do Not Impair Neuromuscular Transmission or Function
Next, we tested whether emGFP-TetC constructs would impair neuromuscular synap-
tic transmission or function, using isometric force of muscle contractions in response to
nerve stimulation and intracellular recordings from individual NMJs.
Figure 7A–D shows twitch and tetanic force responses in wild-type mouse nerve-
muscle preparations evoked before and one hour after incubation in emGFP-1093:TetC
at 50 µg/mL, a concentration that was sufficient to label motor nerve terminals. There
was no discernible effect on nerve-evoked twitch tension or sustained, tetanic muscle
force. Consistent with the functional recordings, intracellular recordings from individual
NMJs, after a similar period of incubation in either full length or truncated emGFP-TetC
constructs, showed no discernible impairment in neuromuscular transmission. For instance,
when we measured EPPs and MEPPs from specific NMJs in mouse ETA muscle, before
and after incubating preparations with a range of concentrations of emGFP-865:TetC
(20–100 µg/mL; Figure 8A,B), there was no significant effect (Figure 8A–E). Similarly, there
was no discernible or significant effect of emGFP-1093:TetC on either EPPs or MEPPs
recorded from muscle fibres sampled with microelectrodes before, during or after washing
emGFP-1093:TetC from media bathing isolated mouse FDB muscles (Figure 8F–I). In these
preparations, mean EPP amplitude (corrected to a resting potential of −70 mV) in MPS
was 15.5 ± 5.0 mV (mean ± SEM, n = 3 muscles, 18 muscle fibres; 95% CI = 12.4–18.6 mV)
and 18.5 ± 5.0 mV after 1 h incubation in 50 µg/mL emGFP-1093:TetC (n = 3 muscles,
16 muscle fibres; 95% CI = 11.8–17.2 mV). One hour after washing preparations with
MPS (when terminals remained labelled) mean EPP amplitude was 15.0 ± 7.0 mV (n = 3
muscles, 17 muscle fibres; 95% CI = 9.5–16.2 mV). None of these differences were significant
(p = 0.74, ANOVA). We did not perform a rigorous quantal analysis in the present study,
which requires analysis of synaptic currents under voltage clamp, but it is implicit from
these voltage data that evoked vesicular release (quantal content) was also unaffected
by incubation in emGFP-TetC constructs. MEPP frequency was also not significantly
altered. In MPS, mean MEPP frequency was 1.29 ± 0.38 s−1 (Mean ± SEM; N = 4 muscles,
n = 68 muscle fibres). After incubation in emGFP-865:TetC, mean MEPP frequency was




Figure 7. emGFP-TetC constructs have no discernible effect on neuromuscular synaptic function.
(A–D): Isometric muscle force recordings of FDB muscle responses to either low frequency (2 Hz)
stimulation producing a train of four twitch responses (A,B) or high frequency (50 Hz, 2 s) stimulation
producing fused tetanic contractions (C,D). There were no discernible differences in the response
characteristics before (in mammalian physiological saline, MPS) or after incubating for 30 min in
emGFP-1093:TetC (50 µg/mL). Similar responses were seen with incubation in other emGFP-TetC
constructs (not shown).


























































































Figure 8. emGFP-TetC constructs do not impair neuromuscular synaptic transmission. (A): LCSM
confocal image of an unfixed, vitally stained motor nerve terminal in a mouse ETA muscle after
incubation for about 30 min in emGFP-865:TetC (50 µg/mL). (B): Intracellular recording of an EPP
from the same NMJ as shown in A, about 30 min after washing emGFP-865:TetC from the recording
chamber. (C–E): Analysis of EPP (C,D) or spontaneous MEPP (E) recordings from specific labelled
NMJs in isolated ETA muscles. (C): open circles represent amplitudes of EPPs recorded in individual
muscle fibres from three preparations, means from each muscle shown by filled circles. (D): Each
point represents the mean EPP responses from one muscle (individual mice) following incubation
in concentrations ranging from 20–100 µg/mL emGFP-865:TetC (see Methods). (E): Each filled
point shows mean MEPP amplitude in one muscle following incubation in emGFP-865:TetC at
the concentrations indicated. Black points in the control column show aggregated mean MEPP
amplitudes from different muscle fibres before adding emGFP-865TetC. There was no significant
effect of incubation in emGFP-865:TetC on either EPP or MEPP amplitudes; p > 0.20 ANOVA for
both EPP and MEPP data. (F,G): Representative intracellular recordings of an EPP (blue trace) and
a MEPP (inset, green trace) recorded from an isolated FDB muscle before (F) and after (G) adding
emGFP-1093:TetC (50 µg/mL) to the recording chamber. (H,I): Summary data from EPP and MEPP
recordings from FDB muscle fibres before and after adding emGFP-1093:TetC. Each filled blue/green
symbol is the mean amplitude of EPPs/MEPPs recorded from one muscle fibre; red circles the mean
values from 3 muscles and the lines indicate mean and standard deviations (SEM). There was no
significant effect of emGFP-1093:TetC (p > 0.7, ANOVA).
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Thus, taking MEPP and EPP measurements together, transmitter release and sensitiv-
ity of AChR to neurotransmitter were affected little, if at all, by incubation and labelling in
emGFP-TetC conjugates at concentrations up to at least 100 µg/mL. By contrast, labelling
postsynaptic acetylcholine receptors (AChR) with fluorescent conjugates of α-bungarotoxin
(5–10 µg/mL), reduced then blocked both nerve-evoked muscle contractions and EPPs
after incubating muscles for more than 10 min (data not shown).
In sum, our electrophysiological analysis suggests that emGFP-1093:TetC and other
TetC constructs, applied at concentrations that produced bright staining of motor nerve
terminals, were physiologically inert from the standpoint of functional neuromuscular
transmission, underscoring the potential utility of emGFP-TetC constructs as inert vital
stains for motor nerve endings, at least in explanted preparations.
3.6. CEM Visualises Adult Nerve Terminals Stained with emGFP-TetC Constructs
Next we tested whether motor nerve terminals labelled with emGFP-TetC or Alexa488-
TetC constructs would be discernible using 1.5 mm diameter, optical-fibre probes coupled
to a single-waveband (488 nm excitation) CEM system. Compared with our previous
attempts using other fluorochromes [21], subcutaneous injection of 50–100 µL of labelled
emGFP-TetC constructs (20–50 µg/mL) into the hind limbs of anaesthetised mice produced
much brighter in situ labelling of NMJs in the vicinity of the injection site that was clearly
visible and with high contrast, using CEM (Supplementary Video S3). As in our previous
studies [20,21], we captured real time image sequences while slowly gliding the optical
fibre probe by hand over the muscle surface. With practice, quite stable image sequences
(videos) were obtained by this method. However, further compensation for image vibration
or drift (‘camera shake’) proved possible by applying the StackReg/TurboReg image
alignment (registration) utility for Fiji to the video recordings (see Methods; Supplementary
Videos S4 and S5).
For further CEM visualisation of nerve terminal staining, we isolated nerve muscle
preparations, stained them by incubation in 20–100 µg/mL emGFP-TetC constructs and
imaged surface NMJs. Figure 9A–D shows still frames from CEM videos of the motor
nerve terminals in mouse TS preparations stained with full length (emGFP-865:TetC),
emGFP-1066:TetC, emGFP-1093:TetC, or emGFP-1109:TetC. Nerve terminal fluorescence
was stable for at least 4hr using emGFP-1066:TetC or emGFP-1093:TetC (Figure 9C; see
also Supplementary Videos S6 and S7) but marked degradation of staining was evident in
images obtained after staining with emGFP-1109:TetC over the same period (Figure 9D).
We also successfully used CEM to visualise NMJs labelled with Alexa488 conjugates of full
length TetC (Supplementary Video S8).
We also examined mouse NMJs 21–28 days after unilateral sciatic nerve crush, when
axons and motor nerve terminals were expected to have regenerated. It proved more
difficult to locate distal hind limb NMJs with certainty in situ compared with those in unop-
erated limbs. In isolated preparations, however, nerve terminals were clearly labelled and
evidence of nerve-terminal and axonal sprouting was visible (Figure 9E). Subsequent LSCM,
after counterstaining endplates with TRITC-α-bungarotoxin, confirmed the reinnervation
of most NMJs, with nerve terminal sprouting evident in some of them (Figure 9F–H).
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α
Figure 9. Single-waveband CEM visualizes NMJs labelled with emGFP-TetC constructs. (A–D): Still
frames from videos of unfixed, vitally stained NMJs obtained by single-waveband CEM, 30–60 min af-
ter incubation in either (A): full length emGFP-865:TetC; (B): emGFP-1066:TetC; (C): emGFP-1093:TetC;
(D): emGFP-1109:TetC. Staining was generally weaker and less stable with emGFP-1109:TetC com-
pared with the other constructs. (E): Still frame from a single-waveband CEM showing a group of
reinnervated NMJs in an isolated mouse EDL muscle, 30 days after crush of the ipsilateral sciatic
nerve and staining of the isolated muscle with emGFP-1093:TetC. Some evidence of axonal sprouting
(cyan arrows) is discernible (NMJs indicated by yellow arrows), (F–H): Merged images obtained by
LCSM imaging of different vitally stained, unfixed NMJs in the EDL muscle, counterstained with
TRITC-α-BTX, arrows indicating sprouts and NMJs, respectively, as in (E).
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3.7. Dual-Waveband CEM Resolves NMJ Pathology in Real Time
We asked next whether dual-waveband CEM (DW-CEM) would enable detection of
abnormal motor innervation of muscle. We answered this by simultaneously visualising
emGFP-TetC constructs bound to presynaptic nerve terminal membranes and a fluorescent
conjugate of α-bungarotoxin bound to postsynaptic motor endplate membranes.
As proof of concept, we first applied DW-CEM to isolated preparations from thy1.2YFP16
transgenic mice, in which motor axons and nerve terminals are endogenously fluorescent due
to expression of YFP in motor neurons. We had shown previously that single waveband CEM
readily detects normal and abnormal motor nerve terminals in these mice [20,21]. Since the
long-wavelength laser excitation in the Cellvizio® DW-CEM is at 660nm, we counterstained
AChR in these preparations with the long wavelength emission conjugate, Alexa647-
α-BTX (fluorescence pseudocoloured red or magenta in Figure 10 and Supplementary
Videos S9–S16). All NMJs showed short- and long- wavelength fluorescence, respectively,
co-localised to NMJs.
We then used DW-CEM to examine isolated mouse muscles stained with emGFP-
TetC constructs (Figure 10D–F; Supplementary Videos S10–S12). For these tests, we incu-
bated hind limb muscles (typically EDL, SOL or FDB) or TS muscles in either full length
emGFP-865:TetC or the strongly-binding variants emGFP-1066:TetC or emGFP-1093:TetC
(20–100 µg/mL). Simultaneously, we stained postsynaptic AChR with Alexa647-α-BTX
(5–10 µg/mL). As in preparations from mice with YFP expression in axon terminals, all
endplates showed co-localisation of nerve terminal and endplate fluorescence. Similar
results were obtained applying DW-CEM to dual-stained rat NMJs (data not shown). We
also attempted to locate NMJs in human muscle tissue explants with DW-CEM, since nerve
terminals stained with emGFP-TetC constructs in these explants were visible using LSCM
(see Figure 4). However, the combination of relatively small size of human NMJs [35,47,48]
and relatively low resolution of DW-CEM, together with high non-specific background
fluorescence due to staining of connective tissue, evidently precluded reliable identification
of NMJs in the human muscle samples supplied, using this method. This was the case
with NMJs stained either with full-length emGFP-865:TetC or with the truncated constructs
emGFP-1066:TetC or emGFP-1093:TetC.
We reverted to mice in order to assess whether pathological abnormalities of motor
innervation were distinguishable with DW-CEM. We imaged NMJs in two lines of mice in
which nerve terminals undergo slow, asynchronous degeneration (Figure 11), specifically,
NMJs in young adult WldS mutant mice following axonal injury and spontaneous degener-
ation of terminals in SOD1G93A mice, a model of ALS [12,20]. In WldS mice, we visualised
NMJs in isolated hind limb muscles 5–6 days after unilateral sciatic nerve section. Our pre-
vious studies established that only about half the axotomised NMJs undergo degeneration
or withdrawal of motor nerve terminals from motor endplates during the first 7 days after
axotomy. The Ube4b-Nmnat2 chimeric protein expressed in WldS motor neurons continues
to protect the remaining motor nerve terminals, resulting in complete or partial occupancy
of their motor endplates [12,39,49,50].
DW-CEM imaging of WldS mouse muscles performed 5–6 days after axotomy clearly
distinguished denervated from innervated NMJs (Figure 11A,C,E; Supplementary Video
S13). Denervated NMJs showed only Alexa647-α-BTX fluorescence, while the remain-
ing, innervated NMJs showed co-localised emGFP-1093:TetC fluorescence. However, the
limited spatial resolution of DW-CEM made it difficult to be certain of differences in the
fractional occupancy of NMJs; that is, NMJs from which motor nerve terminals may have
been undergoing progressive degeneration or withdrawal [12]. Contralateral muscles
stained with emGFP-1093:TetC and Alexa647-α-BTX showed 100% innervation, similar to
that shown in Figure 10D–F (data not shown).
A similar mosaic of denervated and innervated NMJs was apparent using DW-CEM to
examine muscles dissected from liminally symptomatic SOD1G93A mice. Previous studies
have shown that NMJs undergoing spontaneous, progressive denervation in these mice,
associated with loss of muscle function [10,11,20,51–54]. As in axotomized WldS mouse
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muscles, denervated and innervated endplates were readily distinguished by DW-CEM
(Figure 11B,D,F; Supplementary Videos S14–S16). Muscles dissected from SOD1G93A
littermate controls showed 100% innervation of NMJs (data not shown).
α
Figure 10. Dual-waveband CEM (DW-CEM) visualizes innervated NMJs. (A–C): Still frames from
DW-CEM videos showing axons (green) and NMJs (red/yellow) in an isolated, unfixed TS muscle
preparation from a thy1.2YFP16 transgenic mouse, counterstained with Alexa647-BTX (pseudo-
coloured red). (A): YFP fluorescence; (B): Alexa647-BTX; (C): Merged images. See also Supplementary
Video S9. (D–F): Still frames from DW-CEM videos of unfixed, vitally stained preparation showing
motor nerve terminals after staining with emGFP-1093:TetC (D), Alexa647-BTX (E) and the merged
frame (F). See also Supplementary Videos S10–S12.
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Figure 11. DW-CEM distinguishes innervated from denervated NMJs in mice with slow axonal
degeneration. (A,C,E): Still frames from DW-CEM videos of unfixed, vitally stained isolated WldS
mouse EDL muscle, 6 days after sciatic nerve section, which induces slow nerve terminal and
axonal degeneration in this natural mutant. (A): merged channels of fluorescence after incubation
in emGFP-1093:TetC and Alexa647-BTX. See also Supplementary Video S13; (C): magnified image
of the region shown boxed by the yellow rectangle in A, showing denervated (red; Alexa647-BTX
staining only) and innervated (dual staining, yellow) in the same region of the axotomized muscle.
(E): Alternative pseudocolouring (magenta for Alexa647-BTX staining; green for emGFP-1093:TetC
staining; colocalization appears white) of the image shown in (C). (B,D,F): Still frames from DW-CEM
videos of an isolated, unfixed and vitally stained TS muscle from a presymptomatic SOD1G93A
mouse. (B): merged channels of fluorescence after incubation in emGFP-865:TetC and Alexa647-
BTX; (D): magnified image of the region shown boxed by the yellow rectangle in (B), showing
denervated (red; Alexa647-BTX staining only) and innervated (dual staining, yellow) in the same
region of the diseased muscle; cyan arrows indicate instances of innervated NMJs, yellow arrows
indicate examples of denervated NMJs, showing only Alexa647-BTX staining. (F): Alternative
pseudocolouring (magenta for Alexa647-BTX staining, as in (E)) of the image shown in (D).
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Thus, vital staining of nerve terminals with TetC and endplates with α-bungarotoxin
combined with DW-CEM enabled resolution of denervated from innervated NMJs in
two animal models of motor neuron disease. However, further refinements to the spatial
resolution of the CEM method are ultimately required in order to translate this methodology
to visualisation of normal or diseased NMJs in humans.
4. Discussion
Our principal goal in this study was to find effective, physiologically-inert labelled pep-
tides that could be used for vital fluorescent staining of motor nerve terminals at NMJs, with
sufficient contrast for visualisation using minimally invasive live imaging techniques such
as fibre-optic CEM [20,21]. We utilised the tetanus toxin C-fragment for this purpose, noting
also a previous report that truncations of the C-fragment appear to bind more effectively
to their ganglioside receptors with higher affinity than the full-length fragment [30]. The
Results show that incubation of NMJs in rodent muscles with fluorescent constructs greater
than about half the length of the C-fragment of tetanus toxin (that is, up to 206 amino acids
from the C-terminus) are readily and stably stained and visualised, using either conventional
fluorescence microscopy or CEM. Acutely, murine motor nerve terminals labelled with the
TetC fragments showed no overt deficiency in neuromuscular transmission, indicating
possibilities for potentially important applications, combining morphological and physio-
logical investigation of NMJ structure and function [55–58]. We also extended our previous
investigations of the utility of CEM [20,21] by demonstrating that DW-CEM enables live
imaging of motor innervation by simultaneous visualisation of presynaptic terminals (la-
belled with emGFP-865:TetC) and postsynaptic receptors (labelled with Alexa647-BTX).
DW-CEM also readily resolved intact from degenerating motor nerve terminals in mouse
models of progressive axonal and neuromuscular synaptic degeneration.
4.1. Binding of GFP-TetC Derivatives
GFP-TetC derivatives (or Alexa488-TetC conjugates) appear superior in several re-
spects to previous compounds utilised as non-toxic vital stains for NMJs, including nerve
terminal staining using GFP-tagged constructs of the botulinum toxin heavy chain (BoNT-
HC), which we presume to be due to a greater density of binding sites for TetC than for
BoNT-HC [21]. There are also benefits compared with simpler organic molecules such
as styryl dyes like 4-di-2-Asp or FM1-43. For instance, 4-di-2-Asp staining of NMJs is
very effective when viewed with conventional fluorescence microscopes but background
staining is relatively high. Likewise, staining with FM1-43 typically produces significant
background staining, exacerbated by staining of intracellular membranes in any damaged
cells [58–61]. FM1-43 staining also requires nerve stimulation or depolarisation during
loading in order to generate contrast with passive background staining [57,59,62]. However,
FM1-43 and related dyes have the additional attribute of reporting nerve function, since
nerve stimulation of FM1-43 labelled nerve terminals ‘destains’ them at rates that reflect
synaptic vesicle recycling [57,63], which our TetC derivatives do not.
Mutational analysis of the C-fragment suggests that sites for ganglioside sialic acid
binding motifs are located between amino acids 1271–1282, 1214–1219 and a key residue,
amino acid 1290, of the TetC fragment [36,64–66]. It is therefore perhaps surprising that
we saw no staining with constructs clipped at amino acids 1137 or 1214. The same sites
on TetC were reported recently to bind to nidogens, protein constituents in motor nerve
terminals [34]. Perhaps interference between GFP or emGFP, when tagged to the N-
terminus of our TetC constructs in close proximity to these sites interfered with binding
to target molecules on presynaptic terminals. Consistent with this hypothesis, we found
that emGFP-1109:TetC binding appeared less resilient than the longer constructs emGFP-
1066:TetC or emGFP-1093:TetC. By contrast, these two GFP-based fluorochromes appeared,
subjectively, to give even brighter staining than full length emGFP-865:TetC, consistent
with reports that similar truncations of TetC increase binding to target gangliosides [30].
The complexes formed between TetC constructs and their binding sites in nerve terminal
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membranes were evidently diffusible or otherwise mobile in the presynaptic membrane,
since our measurements of FRAP (Figure 2) indicated movement of GFP-TetC receptor
complexes into the bleached region. Based on Equation (1) given by Gaffield et al. [67], the
mobility for the TetC-receptor binding complexes appeared to be orders of magnitude less
than that expected for passive diffusion but more detailed measurements are required to
establish an accurate diffusion coefficient. A critical 47 amino acid sequence required for
binding of the truncated fragment appears to lie between the amino acids at positions 1093
and 1140. However, this region alone was not sufficient for binding. Constructs lacking
10 amino acids from the C-terminus do not bind to ganglioside receptors in neuronal
membranes [30].
An unexplained feature of staining with all our emGFP-TetC derivatives was that in
most preparations there was little or no axonal staining, or axonal staining was limited to
short lengths of preterminal axons, presumably those extending beyond the last Schwann
cell heminode [13,14]. However, in neonatal preparations there was overt axonal staining
(see, for example, Figure 5), and unmyelinated sensory or autonomic axons were overtly
stained in other, adult preparations (see Figure 6). It remains unclear whether the absence
of complete motor axon staining in adult preparations is due to absence of tetanus toxin
receptors or failure of our emGFP-TetC constructs to penetrate the extracellular spaces
restricted by the presence of myelin sheaths. However, the apparent absence of nodal
staining suggests that absence of protein or ganglioside receptors in these regions is a more
likely explanation.
Finally, although our physiological analysis indicated no discernible acute effects of
emGFP-1093:TetC conjugate on neuromuscular physiology, further investigation is required
to establish any potential longer term consequences of administration of fluorescent TetC
derivatives for the integrity of motor neurons, or other cell types.
4.2. Limitations of CEM and Future Prospects
In the context of NMJ imaging, the main strengths of CEM lie with the flexibility and
small diameter of the optical fibre probes, less than that of some muscle biopsy needles,
together with the ability to capture image sequences at relatively rapid, smooth rate (12 fps).
These features enable rapid appraisal of NMJ disposition and integrity. Thus, the principal
advantages of fibre-optic CEM are capability for in situ, real time imaging of fluorescent
structures, using a flexible, hand-held miniature probe. Potentially, CEM enables minimally
invasive live imaging of NMJs in any muscle via a small (<0.5 cm) skin incision, as we
have shown in our previous studies [20,21]. This is not possible using conventional LSCM.
Potential applications include rapid appraisal of neuromuscular synaptic pathology and
electrophysiological characterisation of synaptic structure-function relationships [8,35,68].
However, the short (near zero) working distance and relatively low spatial resolution
of CEM, (constrained by the spacing between optical filaments that make up the optical
probes), are shortcomings that limit image quality and the capacity to resolve small NMJs or
detailed morphology including individual boutons or fine terminal or axonal sprouts. The
optical path length also limits sensitivity and, therefore, bright fluorochromes provide the
best opportunities for distinguishing normal or pathological structure. Moreover, we were
unsuccessful in visualising NMJs in human explants using CEM, even using the truncations
emGFP-1066:TetC or emGFP-1093:TetC. Further advances in minimally invasive or non-
invasive live imaging may therefore be required to fully capitalise on the NMJ staining
capability of fluorescent TetC constructs, or other molecules with high affinity, to visualise
human NMJs in situ. However, emGFP-TetC staining may enable location of NMJs in
motor point biopsies using conventional wide-field fluorescence microscopy or LSCM,
facilitating their investigation with electrophysiological techniques [2,9,47,48]. The present
findings also endorse the possibility that truncated TetC proteins might be effective vehicles
for focal delivery of potential therapeutic agents, for uptake into motor nerve terminals and
transport to motor neuron cell bodies as novel treatments for ALS or other neuromuscular
diseases [26,69–71]. Finally, we could distinguish innervated from denervated NMJs using
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DW-CEM in rodent muscle, so the technique is a potentially valuable one for evaluating
the extent of early signs of neuromuscular disease, at least in animal models of disease, for
example, the SOD1G93A mouse model of ALS, and perhaps other models as well [16,72].
5. Conclusions
Fluorescent derivatives of TetC are useful vital stains for NMJs in species ranging
from rodents to humans. If used in conjunction with low concentrations of fluorescent
conjugates of BTX, even relatively high concentrations of TetC stain NMJs without in-
hibiting neuromuscular transmission. However, significant challenges remain before the
feasibility of using this technique in a clinical context, in human subjects or patients, can be
evaluated in situ. Nevertheless, the fluorescence intensity of TetC conjugates are sufficient
for visualisation of NMJs using confocal endomicroscopy (CEM), at least in animal models
of disease. For instance, dual waveband CEM resolves innervated from denervated NMJs,
counterstained with fluorescent α-bungarotoxin, in mouse models of nerve degeneration
or neuromuscular disease.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
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the planes containing motor terminals labelled with emGFP-865:TetC. Video S2: 3D-projection of
z-series used to generate the maximum intensity projection shown Figure 6B. This video shows at
higher power than Supplementary Video S1 the axonal staining in focal planes above and below
the planes containing motor terminals labelled with emGFP-865:TetC. Video S3: Single-waveband
CEM recording of mouse hind-limb NMJs labelled in situ with emGFP-TetC. Video S4: Single-
waveband CEM recording of isolated mouse TS NMJs labelled with emGFP-1066:TetC. Video S5:
Same single-waveband CEM recording of mouse TS NMJs labelled with emGFP-1066:TetC, after sta-
bilizing translational motion using StackReg/TurboReg imaging utilities. Video S6: Single-waveband
CEM recording of mouse hind-limb NMJs labelled in situ with emGFP-1093:TetC. Video S7: Single-
waveband CEM recording of NMJs, 4 h after isolation and staining with emGFP-1093:TetC. Staining
of unmyelinated axons associated with blood vessels is also evident. Video S8: Single-waveband
CEM recording of isolated mouse TS muscle, NMJs labelled with Alexa488-TetC. Video S9: Dual
waveband CEM (DW-CEM) recording of axons and NMJs in an isolated TS muscle from a transgenic
thy1.2YFP16 mouse, counterstained with Alexa647-α-bungarotoxin. Video S10: DW-CEM record-
ing of motor nerve terminals in an isolated TS muscle, stained with emGFP-1093:TetC. Video S11:
DW-CEM recording of motor endplates in the same isolated TS muscle as shown in Supplementary
Video S10, co-stained with Alexa647-α-bungarotoxin. Video S12: Merged DW-CEM recording of
NMJs in the same isolated TS muscle as shown in Supplementary Videos S10 and S11. Video S13:
Merged DW-CEM recording of NMJs in isolated EDL muscle of a WldS mouse, 6 days after ax-
otomy, showing innervated (green/yellow) and denervated (red only) NMJs after staining with
emGFP-1093:TetC and Alexa647-α-bungarotoxin. Video S14: DW-CEM recording of motor nerve
terminals in an isolated TS muscle from a presymptomatic SOD1G93A transgenic mouse, stained
with emGFP-865:TetC. Video S15: DW-CEM recording of motor endplates in the same isolated TS
muscle from a presymptomatic SOD1G93A transgenic mouse as shown in Supplementary Video S14,
stained with Alexa647-α-bungarotoxin. Video S16: Merged DW-CEM recording of NMJs in the same
isolated TS muscle from a presymptomatic SOD1G93A transgenic mouse as shown in Supplementary
Videos S14 and S15.
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